Home / People / Sarah Hanson
Portrait of Sarah Hanson

Sarah Hanson

Partner

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
CMS Holborn Asia
7 Straits View
Marina One East Tower
#19-01
Singapore 018936
Languages English
Life Sciences & Healthcare

Sarah Hanson is a Co-head of the Life Sciences & Healthcare Sector Group for CMS Cameron McKenna Nabarro Olswang LLP. She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  During her time with the firm she has been on secondment with Warner Lambert (now part of Pfizer). 

more less

"Sarah is 'a fantastic client care partner’ and is ranked as a Leading Individual in Legal 500, 2021 for Life Sciences and Healthcare."

Legal 500, 2021

Sarah Hanson is ranked in Chambers and Partners for Life Sciences: Transactional with Chambers reporting that Sarah ‘has acted on some of the most iconic deals of recent times’ and client feedback including "She has excellent knowledge and experience."

Chambers, 2021

Sarah is ranked in Chambers and Partners for Life Sciences: Transactional with a client reporting "We get fast and clear responses from her and good engagement at all stages. We have had a very positive overall experience."

Chambers

Sarah Hanson is ranked in Tier 2 as a Leading Practitioner in the lifesciences - Transactional category with client feedback including: "We get fast and clear responses from her and good engagement at all stages. We have had a very positive overall experience."

Chambers and Partners, 2020

"Sarah Hanson has acted as our relationship partner and has always responded quickly and helped to select appropriate advisors within the CMS network for each instruction."

Client Feedback, Legal 500

Ranked as a Leading Individual for Commercial Contracts.

Legal 500, 2019

Sarah is ranked in Band 2 as a leading practitioner in the Lifesciences – Transactional category where clients say “She never misses a thing” and “could not be more responsive”

Chambers 2018

Relevant experience

  • Almirall SA on the transfer of its respiratory franchise to AstraZeneca for an initial consideration of USD 875m on completion and up to USD 1.22bn in development, launch and sales related milestone payments.
  • PGT Healthcare LLP in relation to a collaboration with Swisse Wellness Group Party Limited in relation to vitamin, mineral and food supplement products across certain territories.
  • Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.
  • Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell.  We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
  • On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
  • Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
  • hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
  • Bayer Crop Science in relation to the sale of its Norwich based manufacturing business (now Briar Chemicals Limited) to the Aurelius Group.
  • Chugui Pharma Marketing in relation to the license of exclusive commercialisation rights to Swiss based Helsiun group’s innovative ghrelin receptor agonist, anamorelin, for the three major European  pharmaceutical markets.
  • Syncona on its collaboration with the University of Edinburgh Centre for Regenerative Medicine and subsequent establishment and licensing of technology to Resolution Therapeutics.
  • Contura on the divestment of its rights to the Bulkamid product for up to $235m together with the associated manufacturing agreement for supply of Bulkamid with rights to a technology transfer.
  • CooperSurgical on the purchase of Safe Obstetric Systems, the manufacturer of the Fetal Pillow.
  • The shareholders of the Essential Group on its disposal to Gyrus Capital.
     
more less

Memberships & Roles

  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less

Publications

  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference – May 2015
more less

Education

  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less
TMT - Technology, Media & Telecommunications

Sarah Hanson is a Partner in the technology team and is a representative on the management committee of the CMS Commercial Law Group as well as being an active member of the firm’s Technology, Media and Communications sector group.

Sarah Hanson is a Co-head of the Life Sciences & Healthcare Sector Group for CMS Cameron McKenna Nabarro Olswang LLP. 

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  She also provides data privacy advice to clients on a broad range of issues.

more less

Sarah Hanson is ranked in Chambers and Partners for Life Sciences: Transactional with Chambers reporting that Sarah ‘has acted on some of the most iconic deals of recent times’ and client feedback including "She has excellent knowledge and experience."

Chambers, 2021

"Sarah is 'a fantastic client care partner’ and is ranked as a Leading Individual in Legal 500, 2021 for Life Sciences and Healthcare."

Legal 500, 2021

Sarah Hanson is ranked in Tier 2 as a Leading Practitioner in the lifesciences - Transactional category with client feedback including: "We get fast and clear responses from her and good engagement at all stages. We have had a very positive overall experience."

Chambers and Partners, 2020

Ranked as a Leading Individual for Commercial Contracts.

Legal 500, 2019

Sarah is ranked in Band 2 as a leading practitioner in the Lifesciences – Transactional category where clients say “She never misses a thing” and “could not be more responsive”

Chambers 2018

Relevant experience

  • A retail company in relation to a comprehensive IT transformation project with a value of between GBP 1-2bn.  The new IT operating model involves the appointment of a ‘service integrator’ supplier who will manage and integrate all IT services.  The project also involves appointment of multiple IT “service tower” providers.  This includes the following IT services: (i) End User Computing services; (ii) Network services (telecoms networks across company’s entire estate); (iii) Front Office services (front office IT applications including cash and stock management, retail and stock sales, branch accounting); and (iv) Back Office services (back office IT applications including HR, accounting and finance systems).
  • Camelot in respect of the establishment of the Euro Millions lottery and related matters.
  • A global company on its transformative HR outsourcing to deliver a new technology platform and service delivery model across multiple regions.
  • A healthcare company on the adoption of RFID technology to support the management of the supply chain for the distribution of its products from the manufacturer to end users.
  • An international consumer brands company on its bid for the Boots Consumer Healthcare division including structuring various IP licences and manufacturing arrangements.
  • A well-known consumer products company in the outsourcing of its back office IT functions to a major IT provider.
  • A marketing company in relation to a number of contracts with a major supermarket for the design and implementation of various consumer product campaigns.
  • A UK listed company on the agency agreements to be entered into by it with various distributors across Europe.
  • A household name drinks company on the logistics and warehousing arrangements for the supply of products in Europe. 
  • A major retail company on various matters including advising on the terms and conditions for its Christmas catalogue, the supply arrangements with a significant procurer of goods and the establishment of its gift voucher scheme.
more less

Memberships & Roles

  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less

Publications

  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference – May 2015
more less

Education

  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less

Feed

16/02/2021
5G reg­u­la­tion and law in Singa­pore
1. What is the state of 5G de­ploy­ment in your coun­try? 5G de­ploy­ment in Singa­pore is be­ing rolled out in phases. The de­ploy­ment is over­seen by the Singa­pore In­focomm Me­dia De­vel­op­ment Au­thor­ity (IM­DA).5G...
Comparable
04/02/2021
Law and reg­u­la­tion of force ma­jeure in Singa­pore
1. Is there le­gis­la­tion on force ma­jeure in your law sys­tem? No, Singa­pore has no le­gis­la­tion on force ma­jeure. Force ma­jeure clauses are no more than a con­veni­ent way of re­fer­ring to con­trac­tu­al terms...
14/12/2020
Di­git­al health apps and telemedi­cine in Singa­pore
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Comparable
25/09/2020
Gov­ern­ment fund­ing avail­able for health­care en­tit­ies to boost cy­ber se­cur­ity
On 10 Septem­ber 2020, as part of Lon­don Tech Week, Di­git­al In­fra­struc­ture Min­is­ter Matt War­man an­nounced new fund­ing for small and me­di­um sized busi­nesses, such as med­ic­al sup­pli­ers and primary care pro­viders...
22/06/2020
Leg­al term for pay­ments in Singa­pore
1.  Are there any spe­cif­ic leg­al re­quire­ments in re­spect of pay­ment terms? No, there are none. The pay­ment term of a con­tract is agreed between the con­tract­ing parties.  2. Is there a stand­ard pay­ment...
21/05/2020
Autonom­ous vehicles law and reg­u­la­tion in Singa­pore
1. Is the test­ing of AVs (SAE Levels 3-5) per­mit­ted on pub­lic roads in your jur­is­dic­tion?  SAE Levels 3-5: Un­der the Road Traffic (Autonom­ous Mo­tor Vehicles) Rules 2017 (2017 Rules), tri­al of autonom­ous...
17/01/2020
New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
23/12/2019
So­cial Me­dia and mHealth Data EMA / HMA Re­port
New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...
03/09/2019
NICE draft re­com­mend­a­tions on medi­cin­al can­nabis
On 8 Au­gust 2019, the Na­tion­al In­sti­tute for Health & Care Ex­cel­lence (NICE) pub­lished draft guid­ance on pre­scrib­ing can­nabis-based medi­cin­al products for con­sulta­tion (Guid­ance). The Guid­ance will re­place...
12/07/2019
Al­exa will see you now
In a push to­wards ac­cess­ib­il­ity, the NHS and Amazon have partnered to stream NHS-veri­fied in­form­a­tion to UK homes.  Al­exa, Amazon’s voice-as­sisted tech­no­logy, is now cap­able of auto­mat­ic­ally search­ing...
11/03/2019
Pro­gress on the Life Sci­ences Sec­tor Deal 2
The Of­fice for Life Sci­ences has pub­lished its Feb­ru­ary edi­tion of the Life Sci­ences In­dus­tri­al Strategy & Sec­tor Deal News­let­ter (the “News­let­ter”). The News­let­ter provides an up­date on how the strategy...
10/01/2019
Fur­ther guid­ance for life sci­ence com­pan­ies if there is no Brexit deal
Up­dated guid­ance has been is­sued by the UK Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) on how the UK would reg­u­late medi­cines, med­ic­al devices and clin­ic­al tri­als in the event that the...